Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care

Virginia A Triant^{1

2

3

4}, Mark J Siedner^{1

3

4

5}

Affiliations

¹ Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
² Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
³ Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ Harvard Medical School, Boston, Massachusetts, USA.
⁵ Africa Health Research Institute, KwaZulu-Nata, South Africa.

Editorial

Virginia A Triant et al. J Infect Dis. 2020.

. 2020 Feb 3;221(4):498-500.

doi: 10.1093/infdis/jiz482.

Virginia A Triant^{1

2

3

4}, Mark J Siedner^{1

3

4

5}

¹ Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
² Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
³ Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ Harvard Medical School, Boston, Massachusetts, USA.
⁵ Africa Health Research Institute, KwaZulu-Nata, South Africa.

No abstract available

Comment on

Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D, Potard V, Lang S, de Castro N, Cotte L, Duval X, Duvivier C, Grabar S, Mary-Krause M, Partisani M, Ronot-Bregigeon S, Simon A, Tattevin P, Weiss L, Zucman D, Katlama C, Raffi F, Boccara F. Costagliola D, et al. J Infect Dis. 2020 Feb 3;221(4):516-522. doi: 10.1093/infdis/jiz481. J Infect Dis. 2020. PMID: 31828320

1. Feinstein MJ, Hsue PY, Benjamin LA, et al. . Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation 2019; 140:e98–124. - PMC - PubMed
1. Friis-Moller N, Reiss P, Sabin CA, et al. . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723–35. - PubMed
1. Sabin CA, Worm SW, Weber R, et al. . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417–26. - PMC - PubMed
1. Ryom L, Lundgren JD, El-Sadr W, et al. . Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. The lancet HIV 2018; 5:e291–300. - PubMed
1. Kerchberger AM, Sheth AN, Angert CD, et al. . Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis 2019. doi:10.1093/cid/ciz853 - PMC - PubMed